Case Intake
Ingest incoming ICSR reports with AI-powered field extraction
28
Pending Intake
6
AI Extracting
42
Validated
4
Needs Review
Current Case
Case 1 of 28 Pending Intake
Follow-up Required
Yes
Completion
40%
Source Document
PreviewFrom: dr.mitchell@hospital.org
To: safety@pharma.com
Subject: Adverse Event Report — Adalimumab
Dear Safety Team,
I am writing to report an adverse event in my patient, J.D., a 54-year-old male with rheumatoid arthritis who has been receiving Adalimumab 40mg subcutaneously every two weeks since January 2026.
On April 10, 2026, approximately 4 hours after his scheduled injection, the patient developed injection site reaction with erythema, swelling, and pruritus at the injection site.
The reaction was self-limiting and resolved within 48 hours with topical corticosteroid treatment. The patient is recovering. No dose modification is planned at this time.
Please confirm receipt of this report.
Dr. Sarah Mitchell, MD
Rheumatology Department